GLP-1受体激动剂在口腔医学中的前景、隐患与证据缺口
GLP-1受体激动剂(GLP-1RAs)处方量快速增长,但其口腔健康影响尚未充分研究。临床前研究显示其对牙周和种植体周围组织有抗炎与骨保护作用,但缺乏临床研究证据;药物警戒分析报告了口干、味觉障碍等口腔不良反应,胃肠道副作用可能增加牙侵蚀风险。目前尚无前瞻性研究以口腔结局为终点。
要点
- 临床前证据提示GLP-1RAs可能减少牙槽骨吸收并促进种植体骨结合,但仅限体外和动物实验。
- 药物警戒分析显示GLP-1RAs(尤其司美格鲁肽)与口干、味觉障碍和嗅觉丧失相关。
- 恶心(15%–50%)、呕吐(5%–24%)和胃食管反流可能增加牙侵蚀和继发龋风险,但风险未量化。
核心结论
- GLP-1RAs对口腔健康具有潜在益处和风险,但现有证据主要来自临床前研究,临床证据极为有限,亟需前瞻性研究以口腔结局为终点。
研究设计与样本
- 本文为批判性综述,综合多个口腔医学领域的证据并进行分级,识别研究缺口。
- 临床证据仅来自一项回顾性队列研究。
主要发现
- 临床前研究一致显示GLP-1RAs促进牙周膜干细胞成骨分化,减少动物牙周炎模型中的牙槽骨吸收,并增强糖尿病大鼠的种植体骨结合。
- 药物警戒分析报告了口干、味觉障碍和嗅觉丧失等口腔不良反应,尤其与司美格鲁肽相关。
- 胃肠道副作用包括恶心(15%至50%)、呕吐(5%至24%)和胃食管反流,对牙侵蚀和继发龋构成合理但未量化的风险。
- GLP-1信号与口腔微生物群之间存在双向联系,由细菌二肽基肽酶(DPP)-4样酶降解内源性GLP-1介导。
关键数值与推荐
- 肥胖治疗中GLP-1RAs处方量从2019年至2024年增长587%。
- 恶心发生率15%至50%,呕吐发生率5%至24%。
临床怎么用
- 口腔科医生应了解GLP-1RAs可能的口腔不良反应(口干、味觉障碍)及胃肠道副作用相关的牙侵蚀风险。
- 对使用GLP-1RAs的患者,可关注牙周和种植体周围健康,但目前缺乏临床证据支持特异性干预。
局限性
- 临床前发现仅基于体外和动物研究,临床数据仅来自一项回顾性队列研究。
- 尚无前瞻性研究以口腔结局为终点。
- 胃肠道副作用对牙侵蚀和继发龋的风险尚未量化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GLP-1RAs (glucagon-like peptide-1 receptor agonists) have become one of the fastest-growing drug classes worldwide, with prescriptions for obesity treatment increasing by 587% from 2019 to 2024. While their metabolic and cardiovascular benefits are well established, the implications for oral health remain largely unexamined. Preclinical evidence consistently demonstrates anti-inflammatory and osteoprotective effects on periodontal and peri-implant tissues: GLP-1RAs promote osteogenic differentiation of periodontal ligament stem cells, reduce alveolar bone resorption in animal models of periodontitis, and enhance implant osseointegration in diabetic rats. However, these findings are based exclusively on in vitro and animal studies, with only a single retrospective cohort study providing limited clinical data. Conversely, several oral adverse effects have been reported based on pharmacovigilance analyses, including xerostomia, dysgeusia, and anosmia, particularly for semaglutide. Gastrointestinal side effects, particularly nausea (15% to 50%), vomiting (5% to 24%), and gastroesophageal reflux, pose a plausible but unquantified risk for tooth erosion and secondary caries. A bidirectional link between GLP-1 signaling and the oral microbiota, mediated by bacterial dipeptidyl peptidase (DPP)-4-like enzymes that degrade endogenous GLP-1, adds further complexity. Despite this breadth of potential interactions, no prospective study has used any dental outcome as an endpoint in patients receiving GLP-1RAs. This critical appraisal synthesizes the evidence across multiple dental disciplines, grades it in each domain, and identifies the gaps that demand urgent investigation.
引用
- Werner N, Pitchika V, Bumm CV, et al. GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps. J Dent Res. 2026. PMID: 42873199. doi:10.1177/00220345261488338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。